Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
Pharmacyclics LLC.
William G Wierda; John N Allan; Tanya Siddiqi; Thomas J Kipps; Stephen Opat; Alessandra Tedeschi; Xavier C Badoux; Bryone J Kuss; Sharon Jackson; Carol Moreno; Ryan Jacobs; John M Pagel; Ian Flinn; Yvonne Pak; Cathy Zhou; Edith Szafer-Glusman; Joi Ninomoto; James P Dean; Danelle F James; Paolo Ghia; Constantine S Tam